Figure - available from: BMC Bioinformatics
This content is subject to copyright. Terms and conditions apply.
Source publication
Objective
Breast cancer is a significant health issue for women, and human epidermal growth factor receptor-2 (HER2) plays a crucial role as a vital prognostic and predictive factor. The HER2 status is essential for formulating effective treatment plans for breast cancer. However, the assessment of HER2 status using immunohistochemistry (IHC) is ti...
Similar publications
Central nervous system (CNS) tumors comprise nearly 3% of all malignancies world-wide whereas in India it accounts for about 2%. In recent years there has been an increase in CNS tumors with new potential risk factors being observed.
The aim of the present study is to highlight the histopathological spectrum of brain tumors in a single tertiary car...
Citations
... HE-HER2Net acquired almost an accuracy of 0.87, a precision of 0.88, and a recall of 0.86. Finally, Wang et al. [28] proposed HAHNet which combines multi-scale features with attention mechanisms and obtained better results of an accuracy of 93.65%, precision of 93.67% and recall of 92.46%, etc on the same H&E data from BCI dataset. ...
Breast Cancer (BC) is among women’s most lethal health concerns. Early diagnosis can alleviate the mortality rate by helping patients make efficient treatment decisions. Human Epidermal Growth Factor Receptor (HER2) has become one the most lethal subtype of BC. According to the College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO), the severity level of HER2 expression can be classified between 0 and 3+ range. HER2 can be detected effectively from immunohistochemical (IHC) and, hematoxylin & eosin (HE) images of different classes such as 0, 1+, 2+, and 3+. An ensemble approach integrated with threshold filtered single instance evaluation (SIE) technique has been proposed in this study to diagnose BC from the multi-categorical expression of HER2 subtypes. Initially, DenseNet201 and Xception have been ensembled into a single classifier as feature extractors with an effective combination of global average pooling, dropout layer, dense layer with a swish activation function, and l2 regularizer, batch normalization, etc. After that, extracted features has been processed through single instance evaluation (SIE) to determine different confidence levels and adjust decision boundary among the imbalanced classes. This study has been conducted on the BC immunohistochemical (BCI) dataset, which is classified by pathologists into four stages of HER2 BC. This proposed approach known as DenseNet201-Xception-SIE with a threshold value of 0.7 surpassed all other existing state-of-art models with an accuracy of 97.12%, precision of 97.15%, and recall of 97.68% on H&E data and, accuracy of 97.56%, precision of 97.57%, and recall of 98.00% on IHC data respectively, maintaining momentous improvement. Finally, Grad-CAM and Guided Grad-CAM have been employed in this study to interpret, how TL-based model works on the histopathology dataset and make decisions from the data.
... HE-HER2Net acquired almost an accuracy of 0.87, a precision of 0.88, and a recall of 0.86. Finally, Wang et al. [29] proposed HAHNet which combines multi-scale features with attention mechanisms and obtained better results of an accuracy of 93.65%, precision of 93.67% and recall of 92.46%, etc on the same H&E data from BCI dataset. ...
Breast Cancer (BC) is among women's most lethal health concerns. Early diagnosis can alleviate the mortality rate by helping patients make efficient treatment decisions. Human Epidermal Growth Factor Receptor (HER2) has become one the most lethal subtype of BC. According to the College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO), the severity level of HER2 expression can be classified between 0 and 3+ range. HER2 can be detected effectively from immunohistochemical (IHC) and, hematoxylin \& eosin (HE) images of different classes such as 0, 1+, 2+, and 3+. An ensemble approach integrated with threshold filtered single instance evaluation (SIE) technique has been proposed in this study to diagnose BC from the multi-categorical expression of HER2 subtypes. Initially, DenseNet201 and Xception have been ensembled into a single classifier as feature extractors with an effective combination of global average pooling, dropout layer, dense layer with a swish activation function, and l2 regularizer, batch normalization, etc. After that, extracted features has been processed through single instance evaluation (SIE) to determine different confidence levels and adjust decision boundary among the imbalanced classes. This study has been conducted on the BC immunohistochemical (BCI) dataset, which is classified by pathologists into four stages of HER2 BC. This proposed approach known as DenseNet201-Xception-SIE with a threshold value of 0.7 surpassed all other existing state-of-art models with an accuracy of 97.12\%, precision of 97.15\%, and recall of 97.68\% on H\&E data and, accuracy of 97.56\%, precision of 97.57\%, and recall of 98.00\% on IHC data respectively, maintaining momentous improvement. Finally, Grad-CAM and Guided Grad-CAM have been employed in this study to interpret, how TL-based model works on the histopathology dataset and make decisions from the data.
The Human Epidermal Growth Factor Receptor 2 (HER2) is one of the aggressive subtypes of breast cancer. The HER2 status decides the requirement of breast cancer patients to receive HER2-targeted therapy. The HER2 testing involves combining Immunohistochemistry (IHC) screening, followed by fluorescence in situ hybridization (FISH) for cases where IHC results are equivocal. These tests may involve multiple trials, are time intensive, and tend to be more expensive for certain classes of people. Hematoxylin and Eosin (HE) staining is employed for visualizing general tissue morphology and is a routine, cost-effective method. In this study, we introduce a novel automated class-wise weighted average ensemble deep learning algorithm at the decision level. The proposed algorithm fuses three pre-trained deep-learning models at the decision level by assigning a weight to each class based on their performance of the model to classify the HE-stained breast histopathology images into multi-class HER2 statuses as HER2-0+, HER2-1+, HER2-2+, and HER2-3+. The class-wise weight allocation to the base classifiers is one of the key features of the proposed algorithm. The presented framework surpasses all the existing methods currently employed on the Breast Cancer Immunohistochemistry (BCI) dataset, establishing itself as a dependable approach for detecting HER2 status from HE-stained images. This study highlights the robustness of the proposed algorithm as well as the sufficient information encapsulated within HE-stained images for the effective detection of the HER2 protein present in breast cancer. Therefore, the proposed method possesses the potential to sideline the need for IHC laboratory tests, which hoard time and money.
